Suppression of tumorigenesis by human mesenchymal stem cells in a hepatoma model

Ling Qiao1, Zhili Xu, Tiejun Zhao

  • 1Department of Biochemistry, College of Life Sciences, Nankai University, Tianjin 300071, China.

Cell Research
|March 28, 2008
PubMed

Insights

Human mesenchymal stem cells (hMSCs) inhibit liver cancer growth by decreasing proliferation and oncogene expression. These findings suggest the Wnt signaling pathway plays a role in hMSC-mediated tumor cell inhibition.

Area of Science:

  • Oncology
  • Stem Cell Biology
  • Molecular Biology

Background:

  • Human mesenchymal stem cells (hMSCs) exhibit tumor-homing properties and can inhibit tumor growth.
  • The molecular mechanisms underlying hMSC-mediated tumor inhibition are not fully understood.

Purpose of the Study:

  • To investigate the effects of hMSCs on human hepatoma cell lines (H7402 and HepG2).
  • To elucidate the molecular mechanisms involved in hMSC-mediated inhibition of liver cancer cell lines.

Main Methods:

  • Animal transplantation models using SCID mice.
  • In vitro co-culture systems with hMSCs and hepatoma cell lines.
  • Treatment with conditioned media from hMSC cultures.
  • Immunoblot analysis to assess protein expression.

Main Results:

  • hMSCs prolonged tumor formation latency and reduced tumor size in vivo.
  • Co-culture with hMSCs decreased hepatoma cell proliferation and increased apoptosis.
  • hMSCs downregulated key oncogenes including Bcl-2, c-Myc, PCNA, and survivin.
  • Conditioned media from hMSCs reduced hepatoma cell colony-forming ability and proliferation.
  • Western blot confirmed downregulation of beta-catenin, Bcl-2, c-Myc, PCNA, and survivin.

Conclusions:

  • hMSCs effectively inhibit malignant phenotypes of human liver cancer cell lines in vitro and in vivo.
  • hMSCs suppress proliferation, colony formation, and oncogene expression in hepatoma cells.
  • The Wnt signaling pathway is implicated in hMSC-mediated tumor cell targeting and inhibition.